COYA•benzinga•
Coya Therapeutics Completes Controlled Phase 2 Study Of Low Dose Interleukin-2 In Patients With Alzheimer's Disease
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 22, 2024 by benzinga